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Herpes simplex type 2-defective infectious single-cycle (DISC) viruses are attenuated viruses that were originally produced as viral
vaccines; however, these viruses are also efficient gene transfer vehicles. The main goals of this study were to examine determinants
of the gene transfer by using DISC virus for squamous cancer and to evaluate the antitumoral efficacy of vaccination with tumor cells
modified by DISC viruses carrying a combination of immunomodulatory genes (interleukin-2 (IL-2), granulocyte-macrophage
colony-stimulating factor (GM-CSF), B7-1) in a model of squamous cell cancer (SCCVII) in C3H/HeJ mice. SCCVII cells transduced
by DISC viruses (multiplicity of infection of 10) carrying the IL-2 or GM-CSF gene produced nanogram quantities of IL-2 or GM-CSF
per 106 cells. Irradiated (5,000 cGy, 10,000 cGy) cells secreted levels of GM-CSF or IL-2 that were comparable with nonirradiated
cells. In vivo vaccination using tumor cells transduced ex vivo with DISC-IL2 or DISC-GMCSF resulted in protection against
subsequent tumor challenge (P , .01), with DISC-GMCSF-transduced, irradiated tumor cells showing the greatest effects (P , .001).
Marked growth arrest also was noted in established tumors after direct injection of DISC-GMCSF (P , .001). These data demonstrate
that (a) DISC virus is capable of efficient gene transfer, (b) GM-CSF-secreting genetically modified tumor vaccine protects against
tumor cell challenge and suppresses tumor growth, and (c) intratumoral injection of DISC-GMCSF significantly suppresses the
growth of established tumors. These results not only confirm clinically relevant gene transfer but also demonstrate that the gene
transfer is an effective anti-cancer therapy. Cancer Gene Therapy (2000) 7, 1279–1285
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colony-stimulating factor.
Cancer of the head and neck region represents 6.6%of all new cases of malignant disease in United
States.1 One-half of patients with squamous cell cancer
of the head and neck present with advanced stage
disease, and only approximately one-third of these pa-
tients survive 5 years with presently available therapies.2
The cohort of head and neck cancer patients with
advanced disease awaits the development of novel ther-
apies to improve loco-regional control and survival while
limiting functional morbidity. Several gene therapy strat-
egies have been evaluated as treatments of squamous
cell carcinomas of the head and neck,3–5 including the
use of tumor vaccines consisting of irradiated, nondivid-
ing tumor cells genetically engineered to secrete cyto-
kines.4–9 Many gene transfer vehicles have been used in
this regard, including retroviral vectors, adenoviral vec-
tors, and physical means, in attempts to enhance host
tumor surveillance by expressing immunostimulatory
molecules at the site of putative tumor antigens
(Ags).10–13 Replication-defective amplicon vectors
based on herpes simplex virus type 1 (HSV-1) also have
been used and have many characteristics highly desirable
for such gene transfer. They have the ability to accom-
modate large inserts, to transduce a variety of cell types,
and to transduce slowly replicating or even nonreplicat-
ing cells.14–16
The defective infectious single-cycle (DISC) virus
vector is a HSV-2 virus that is deficient in the gene
coding the envelope glycoprotein H (gH), which is
essential for the virus to infect cells. When packaged in
a complimentary cell line, the DISC viruses produced
can infect and transfer their genetic material to a cell,
but the viral progeny subsequently produced are nonin-
fective. The safety of such DISC viruses in preclinical
studies has been well documented.17,18 Furthermore,
these viruses were originally designed to be viral vac-
cines and as such are in clinical trials.19 Current studies
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are examining DISC viruses modified to contain genes
encoding interleukin-2 (IL-2), granulocyte-macrophage
colony-stimulating factor (GM-CSF), and B7-1, which
are immunomodulatory agents showing great promise in
the treatment of cancer.16,20–23 The main goals of this
study were to study the determinants of gene transfer to
squamous cancers (SCCVII) using DISC viruses and to
evaluate the utility of vaccination with DISC viruses
carrying a combination of immunomodulatory genes as
cancer therapy.
MATERIALS AND METHODS
Mice
Female C3H/HeJ mice (The Jackson Laboratory, Bar Harbor,
Me), 6–8 weeks of age, were maintained in specific pathogen-
free conditions and were used for experiments at $8 weeks of
age. The SCCVII tumor is a poorly immunogenic cell line
previously used in immunocompetent mice, and has been
shown to closely parallel the clinical and biological nature of
head and neck cancer.24 The experimental protocol was re-
viewed and approved by the Institutional Animal Care Com-
mittee of the Memorial Sloan-Kettering Cancer Center.
Cell culture
The SCCVII cell line was a gift from Ditmar Seeman (Univer-
sity of Florida, Gainesville, Fla). It is a cutaneous squamous
cell cancer that spontaneously arose in the C3H/HeJ mouse.
For in vitro studies, cells were grown in minimal essential
media supplemented with 10% fetal calf serum at 37°C in a 5%
CO2 humidified atmosphere and subcultured twice a week.
Viruses: Preparation of DISC herpes virus vector
DISC virus vectors were derived from the wild-type strain of
HSV-2 known as strain HG52 and modified by deletion of the
gH gene. It was constructed and prepared as described previ-
ously.18,25 The gH-deleted HSV-2 strain HG52 was propagated
and titrated on a complementing Vero cell line that expresses
the HSV-2 gH gene. Human IL-2, murine GM-CSF, or murine
B7-1 genes were inserted into the genome of HSV-2 strain
HG52 in place of the gH gene using the recombinant vector
PIMR3. The resulting recombinant viruses were termed DISC-
IL2, DISC-GMCSF, and DISC-B7, respectively. The func-
tional copies of these cytokine genes are under control of a
cytomegalovirus immediate-early promoter. The multiplicity of
infection (MOI) for the experiments described herein were
based on plaque-forming unit (PFU) assays on CR1 cells.
DISC virus stocks were stored at 280°C until use.
In vitro experiments: Transduction of SCCVII cells and
demonstration of IL-2 and GM-CSF production
SCCVII murine squamous cell carcinoma cells were plated in
6-well, flat-bottom plates at a density of 1 3 106 cells/well.
After 12 hours, the cells were irradiated: control cells received
no irradiation, whereas the other groups were irradiated with
5,000 cGy and 10,000 cGy. The wells were then infected with
DISC-IL2 or DISC-GMCSF vectors for 2 hours at MOIs of 0,
1, 5, 10, and 20 by adding the appropriate concentration of
virus in 1 mL of medium. After 2 hours of exposure to virus,
the wells were washed three times with phosphate-buffered
saline (PBS) and 2 mL of medium was added after the final
wash. All assays were performed in duplicate, and control wells
were treated with medium alone. After 24 hours of incubation,
the supernatants were collected and centrifuged at 1500 rpm
for 5 minutes. Subsequently, GM-CSF and IL-2 levels were
quantified by enzyme-linked immunosorbent assay (ELISA) as
described previously (R&D Systems, Minneapolis, Minn).
In vivo experiments
In vivo effect of gene transfer of multiple immunomodulatory
transgenes on subsequent tumor challenge. C3H/HeJ mice were
randomly divided into eight groups (n 5 10/group). In the test
groups, the animals were vaccinated by subcutaneous (s.c.)
injection of irradiated SCCVII cells (volume of 50 mL) that
had been exposed to various combinations of DISC viruses
carrying immunomodulatory transgenes; animals in the control
group received a s.c. injection of PBS or irradiated tumor cells
alone. In previous experiments, we have demonstrated that
tumor cells infected with DISC virus carrying the b-galactosi-
dase gene produced no detectable amounts of IL-2 or GM-
CSF, and vaccination with tumor cells so modified produced
effects that were no different from vaccination with irradiated,
noninfected tumor cells. Other groups studying colorectal
cancers26 or hemopoietic malignancies17 made this same ob-
servation. Therefore, in these experiments, to simplify the
study design, irradiated tumor cells were used as controls. The
mice were vaccinated every 2 days to a total of three doses. The
SCCVII cells used for the vaccination were first irradiated to a
dose of 10,000 cGy using a 137Cs source. Next, 1 3 106 of the
SCCVII cells were exposed to one of the various DISC vectors
at a MOI of 10. A s.c. injection was delivered in a volume of 50
mL to the various experimental groups as follows: group I
(control), PBS alone; group II, irradiated SCCVII cell alone;
group III, DISC-IL2-transduced SCCVII; group IV, DISC-
IL2- and DISC-B7-transduced SCCVII; group V, DISC-
GMCSF-transduced SCCVII; group VI, DISC-GMCSF- and
DISC-B7-transduced SCCVII; group VII, DISC-GMCSF- and
DISC-IL2-transduced SCCVII; and group VIII, DISC-
GMCSF-, DISC-IL2-, and DISC-B7-transduced SCCVII. Dur-
ing all injections of tumor cells or viruses, the animals were
anesthetized with pentobarbital (50 mg/kg intraperitoneally).
After 1 week, the mice were challenged with 1 3 105 SCCVII
tumor cells (volume of 50 mL) injected into each flank. The
animals were examined daily, and body weights and tumor
volumes were recorded three times a week. Tumor volume was
assessed by assuming the shape to be that of a prolate spheroid
with semi-axes “a” and “b” being one-half of the two maximal
dimensions, and volume equal to 4/3pab2.
In vivo effects of DISC-GMCSF on established tumors. C3H/
HeJ mice were randomly divided into three groups. In each
group, bilateral s.c. flank tumors were established by injecting
1 3 106 (volume of 50 mL) SCCVII tumor cells. The animals
were monitored on a daily basis for tumor growth until the
implanted tumors reached 0.5 cm in maximum diameter. From
prior experience, it takes ;5 days for a 0.5-cm tumor nodule to
form. At that time, one of the following preparations was
injected every 2 days to a total of three doses intratumorally
(i.t.): group I (control), PBS alone; group II, 5 3 106 PFU
heat-inactivated DISC-GMCSF (70°C 3 5 minutes); group III,
5 3 106 PFU DISC-GMCSF (volume of 50 mL). The animals
were examined daily, and body weights and tumor volumes
were recorded as described above.
Determination of in vivo GM-CSF production. Flank tumors
were established in C3H/HeJ mice by injecting 1 3 106
SCCVII tumor cells s.c. When the tumor nodules became
palpable (;0.5 cm in diameter), animals were treated in the
following groups: group 1 (control), PBS alone; group 2, 5 3
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106 PFU heat-inactivated DISC-GMCSF; group 3, 5 3 106
PFU DISC-GMCSF. Two animals in each group were sacri-
ficed at 24, 48, and 72 hours after i.t. injection and tumors were
harvested for analysis. Each tumor was weighed, and tumor
lysates were prepared for determination of GM-CSF levels by
ELISA (R&D Systems).
Determination of i.t. infiltration of CD41, CD81, and CD45R1
cells. Mice with established tumors (1 cm in diameter) were
injected with three doses of PBS (group 1), 5 3 106 PFU
heat-inactivated DISC-GMCSF (group 2), or 5 3 106 PFU
DISC-GMCSF (group 3) given i.t. 2 days apart. Animals were
sacrificed 7 days after the last i.t. injection and their tumors
were harvested for analysis of the surface phenotype of tumor-
infiltrating cells. Tumor cell suspensions were prepared by
mincing the tumors and digesting them in collagenase (0.1%)
for 45 minutes at 37°C and then washing them in PBS. Cells
were then stained with anti-murine CD4 (09005A; PharMin-
gen, San Diego, Calif) (1:100), anti-murine CD8 (01044A;
PharMingen) (1:100), and anti-murine CD45R (01125A;
PharMingen) (1:100) monoclonal antibodies. A fluorescein
isothiocyanate-labeled antibody was used to detect CD81 cells.
CD41 or CD45R1 cells also were stained with a phyco-
erythrin-labeled antibody. Flow cytometric analysis was per-
formed using a FACScan (Becton Dickinson, San Jose, Calif)
and the percentages of CD81, CD41, and CD45R1 cells were
calculated in all tumor tissue.
Statistical analysis
All data are expressed as the mean 6 SE. Comparisons
between groups were made using a two-tailed Student’s t test.
An analysis of variance test, where appropriate, was used to
identify statistical significance for multiple comparisons.
RESULTS
In vitro demonstration of GM-CSF and IL-2 production
in SCCVII cells
Production of GM-CSF or IL-2 from SCCVII cells
exposed to the DISC-GMCSF or DISC-IL2 viruses,
respectively, at MOIs of 1, 5, 10, and 20 was determined
by ELISA. IL-2 production ranged from 2000 to 9000
pg/million cells and GM-CSF production ranged from
1800 to 7000 pg/million cells, depending upon the MOI.
SCCVII cells before DISC-GMCSF or DISC-IL2 infec-
tion produced no GM-CSF or IL-2. Of particular inter-
est was the observation that cells subjected to irradiation
(5,000 cGy, 10,000 cGy) secreted levels of GM-CSF or
IL-2 that were comparable with the levels seen for
nonirradiated cells (Fig 1). This confirms efficient DISC
virus-mediated gene transfer even to nonreplicating
cells.
In vivo effect of gene transfer of multiple
immunomodulatory transgenes on subsequent tumor
challenge
Animals were vaccinated by s.c. injection of irradiated
SCCVII cells (volume of 50 mL) that had been exposed
to the DISC virus carrying one of various immunomodu-
latory transgenes. At 1 week after the third dose, the
mice underwent a tumor challenge with 1 3 105 SCCVII
tumor cells (volume of 50 mL) injected into each flank.
Immunization with DISC-containing immunomodula-
tory genes significantly reduced tumor growth (Fig 2, A
and B). This resulted in a significant improvement in
survival (P , .001) (Fig 3). There was no significant
effect of vaccination with irradiated SCCVII cells.
Among the multiple immunomodulatory transgene vac-
cination groups, treatment regimens containing GM-
CSF showed the greatest protection against tumor
growth. Most importantly, vaccination with GM-CSF
alone proved to be equally efficient in preventing tumor
development and growth as a combination of GM-CSF
with IL-2, B7, or both.
In vivo effects of DISC-GMCSF on established tumors
Because of the above-mentioned findings, we chose to
test only DISC-GMCSF in the experiment with estab-
lished tumors. SCCVII tumors were established in s.c.
tissue on the flanks of C3H/HeJ mice. Once tumors had
reached ;5 mm in diameter, PBS, 5 3 106 PFU
heat-inactivated DISC-GMCSF, or 5 3 106 PFU DISC-
GMCSF virus was injected i.t. As seen in Figure 4,
inhibition of tumor growth was seen in the DISC-
GMCSF-treated group (P , .001). In contrast, heat-
inactivated DISC-GMCSF showed no significant tumor-
suppressive effect.
Figure 1. IL-2 (A) and GM-CSF (B) production by SCCVII cells
modified by DISC-IL2 and DISC-GMCSF, respectively. Detection
was by ELISA at 24 hours posttransduction. SCCVII cells before
DISC-GMCSF or DISC-IL2 infection produced no GM-CSF or IL-2.
Of particular interest was the observation that cells irradiated at
different doses (5,000 cGy, 10,000 cGy) secreted levels of GM-CSF
or IL-2 that were comparable with the level observed for nonirradi-
ated cells. All data are expressed as mean 6 SE.
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Determination of in vivo GM-CSF production
Tumors that were injected with PBS or the 5 3 106 PFU
heat-inactivated DISC-GMCSF virus had GM-CSF lev-
els that were below detectable limits, as seen in Figure 5.
The group that underwent DISC-GMCSF i.t. injection
had significant concentration levels, which exceeded
4500 pg/0.5 g of tumor tissue, but the production de-
creased markedly over time.
Determination of i.t. infiltration of CD81, CD41, and
CD45R1 cells
The proportion of CD41 and CD81 cells seen in the
tumors is shown in Figure 6, A and B. It is interesting to
note that the injection of DISC-GMCSF resulted in a
significant elevation in the percentage of CD81 cells in
the tumors compared with treatment with PBS or heat-
inactivated DISC-GMCSF (P , .05). Also, there was
significant elevation of the percentage of CD41 cells in
comparison with the PBS-treated group. The i.t. infiltra-
tion of CD45R1 cells was not significantly increased
compared with control groups.
DISCUSSION
The prognosis of patients with advanced stage head and
neck squamous cell cancer remains poor despite aggres-
sive therapies combining surgery, chemotherapy, and
radiation therapy. Preclinical studies evaluating viral
vector-mediated gene transfer in the treatment of head
and neck squamous cell cancer have reported promising
preclinical results.3–5 Among these gene therapy strate-
gies are efforts to augment the immune response of the
host to cancer by using tumor vaccines27–30 to increase
the tumoricidal activity of the immune system and to
generate lasting immunological memory against tumor
cells. One method for using genetically modified tumor
vaccines for enhancement of anti-cancer immunity in-
volves introducing genes encoding immunostimulatory
molecules into tumor cells in the hope that these com-
pounds will be expressed and secreted in proximity to
the tumor cells and putative tumor Ags. Thus, they may
provide immunostimulatory signals at the site of the
evolving immune response to obviate or reduce the need
for CD41 T cells, which are thought to be a limiting
factor in the generation of an effective antitumoral
response.11,27,31 The genes GM-CSF, IL-2, and B7-1
were chosen for the current experiments because they
have been shown to be promising immunostimulatory
molecules in other models.27,28,32,33 The main function
Figure 2. Effect of vaccination with SCCVII cells transduced with
various DISC viral constructs on tumor growth in a syngeneic tumor
model. A: All treated groups were significantly different from groups
treated with PBS or irradiated SCC. Among the multiple immuno-
modulatory transgene vaccination groups, combinations that in-
cluded GM-CSF showed the greatest antitumoral protection. B: Box
plots demonstrating the effect of vaccination with SCCVII cells
modified with various DISC constructs. Data indicate tumor size at
day 21 after tumor inoculation in C3H/HeJ mice. p, P , .01 for each
treated group versus PBS or irradiated SCC controls. PBS, PBS
controls; Irr. SCCVII, irradiated SCCVII cells; IL2, DISC-IL2-trans-
duced SCCVII cells; IL21B7, DISC-IL2- and DISC-B7-transduced
SCCVII cells; GMCSF, DISC-GMCSF-transduced SCCVII cells;
GMCSF1B7, DISC-GMCSF- and DISC-B7-transduced SCCVII
cells; GMCSF1IL2, DISC-GMCSF- and DISC-IL2-transduced SC-
CVII cells; GMCSF1IL21B7, DISC-GMCSF-, DISC-IL2-, and DISC-
B7-transduced SCCVII cells.
Figure 3. Effect of vaccination with SCCVII cells transduced with
various DISC viral constructs on tumor-free survival in a C3H/HeJ
syngeneic tumor model. The groups tested are described in the
legend to Figure 2. The tumor-free survival of mice from the
GM-CSF group was significantly better than that seen for the mice
from the IL-2 group (log rank test, P , .001: GMCSF versus PBS or
Irr. SCCVII, GMCSF1B7 versus PBS or Irr. SCCVII, GMCSF1IL2
versus PBS or Irr. SCCVII, or GMCSF1IL21B7 versus PBS or Irr.
SCCVII).
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of IL-2 is activation and stimulation of major histocom-
patibility complex (MHC) class II-restricted CD4 cells to
mediate efficient induction of a MHC class I-restricted
cytotoxic T-cell response. GM-CSF is a major stimula-
tory cytokine for the maturation and activation of Ag-
presenting cells. It also augments the expression of
MHC molecules on Ag-presenting cells such as macro-
phages and dendritic cells. B7-1 is a costimulatory
molecule that augments an existing immune re-
sponse.27–36 There are theoretical reasons to suppose
that the expression of a combination of these molecules
would be more effective at eliciting an antitumoral
response than the expression of each alone. The premise
of the current experiments is that DISC viruses can
produce efficient transfer of these genes to tumor cells
and elicit antitumoral responses. The results not only
confirm clinically relevant gene transfer but also dem-
onstrate that the gene transfer is an effective anti-cancer
therapy.
The majority of past gene transfer approaches use
adenoviral vectors and retroviral vectors to transfer
therapeutic genes.28,37 Recent work from our laboratory
also has demonstrated that HSV amplicon vectors pro-
vide efficient gene transfer in head and neck squamous
cancer cells and gastrointestinal cancers.15,38–40 HSVs
have a natural affinity for neural tissue, and these vectors
systems were originally designed for gene transfer into
the nervous system.23,41 The natural life cycle of the
Figure 4. A,B: Effect of DISC-GMCSF injection on an established
syngeneic tumor model. At day 14 after the last DISC-GMCSF
injection, a great inhibition of tumor growth was seen in the
DISC-GMCSF-treated group. In contrast, treatment with heat-inac-
tivated DISC-GMCSF showed no significant tumor suppression
effect. p, P , .001, control versus DISC-GMCSF; #, P , .01, heat
DISC-GMCSF versus DISC-GMCSF. All data are expressed as
mean 6 SE.
Figure 5. In vivo GM-CSF concentration after i.t. DISC-GMCSF
injection. The group that underwent the 5 3 106 PFU DISC-GMCSF
i.t. injection had significant concentration levels, which exceeded
4500 pg/0.5 g of tumor tissue.
Figure 6. A,B: Flow cytometric analysis for tumor-infiltrating CD81
and CD41 lymphocytes. A: Treatment of DISC-GMCSF resulted in a
significant elevation in the percentage of CD81 cells in the tumors
compared with the PBS or heat-inactivated DISC-GMCSF-treated
group. B: There was also a significant elevation in the percentage of
CD41 cells compared with the PBS-treated group. p, P , .05,
control versus DISC-GMCSF; #, P , .05, heat DISC-GMCSF versus
DISC-GMCSF.
KIM, CAREW, KOOBY, ET AL: COMBINATION GENE THERAPY WITH IMMUNOMODULATORY GENES 1283
Cancer Gene Therapy, Vol 7, No 9, 2000
HSV involves an initial infection of a cutaneous or
mucosal surface followed by a lytic replication cycle.
Considering its natural cycle, it is not surprising that
HSV vectors are efficient vehicles for gene transfer to
the epithelial-derived SCCVII cells. Using HSV vectors
for gene transfer has many advantages. It allows multiple
gene insertion due to its large genome size (150 kbp). It
also is capable of rapidly and efficiently infecting a
variety of cell types and has the ability to transduce
nonreplicating or slowly replicating cells.15,41 Efficient
transduction of irradiated, nondividing tumor cells is a
critical factor in the ability to produce a genetically
modified tumor vaccine.
Because of some technical obstacles in amplicon
production, we examined the possibility of using DISC
viruses based on HSV-2. The current results demon-
strate that DISC viruses also are efficient gene transfer
vehicles. These DISC viruses have many features in
common with HSV-1 amplicons in that they can accom-
modate large insert sizes and infect nondividing cells
efficiently and rapidly. The cytomegalovirus early pro-
moter-driven expression of a transgene coding for IL-2
or GM-CSF resulted in high levels of protein production
by these transduced cells. These studies demonstrate
that DISC-HSV vectors are potentially useful tools for
the clinical production of tumor vaccine, because they
can transduce irradiated, nonreplicating cells rapidly
and efficiently and produce biological effects. These
physical properties of HSV translate into important
clinical advantages. Freshly isolated tumor cells may be
transduced without the need to provide a tissue culture
environment conducive to cell replication.
The administration of irradiated SCCVII cells trans-
duced by DISC-GMCSF or DISC-IL2 led to inhibition
of tumor growth, whereas tumors treated with irradiated
unmodified SCCVII cells continued to progress rapidly.
The vaccination of animals with SCCVII tumor cells
expressing GM-CSF or IL-2 induced active immunity. A
significant percentage of mice that underwent a subse-
quent challenge with wild-type SCCVII cells did not
develop tumors, whereas all control animals developed
tumors by day 7 after tumor challenge. Among the
animals treated by tumor vaccines exposed to multiple
DISC viruses, combinations involving the use of DISC-
GMCSF showed the greatest suppressive effects on
tumor growth. In the current model, no advantage was
gained by adding other immunostimulatory genes to the
DISC-GMCSF treatment. Whether combinations of
chemokines, costimulatory/adhesion molecules, and cy-
tokines would work better together than each alone in
human disease, where more heterogeneous tumors and
more disparate tumor locations are encountered, can
only be answered by future human trials.
Clinically relevant gene transfer is also possible by
direct injection of tumors in situ. This is particularly
important for head and neck cancers, where patients
often will have had surgical resection and radiation as
treatment at the primary local site, which is also the most
common site of first recurrence. Excision and ex vivo
tumor transduction to produce a tumor vaccine would be
hindered by technical difficulties of operating in this
scarred area. The current data indicate that direct injection
into the tumor may be sufficient to produce biological
effects on established tumors. I.t. injection of DISC-
GMCSF resulted in effective in vivo production of the
cytokine, with clear antitumoral effects. These data, along
with the record of safety seen in trials of DISC viruses as
antiviral vaccines, support a clinical examination of DISC
viruses as a therapy for head and neck cancers.
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